Trial Profile
A phase IIIB, multi-center, randomized, double-blind, placebo-controlled comparative study of abatacept or infliximab in combination with methotrexate in controlling disease activity in subjects with rheumatoid arthritis having an inadequate clinical response to methotrexate
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Infliximab; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms ATTEST
- Sponsors Bristol-Myers Squibb
- 12 Aug 2018 Results from AMPLE and ATTEST trials published in the Clinical and Experimental Rheumatology
- 07 Nov 2012 Planned number of patients changed from 400 to 675 as reported by European Clinical Trials Database record
- 04 Oct 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.